Zacks Bull and Bear of the Day Highlights: AMERISAFE, Scholastic,
GlaxoSmithKline, Novartis and Sanofi
CHICAGO, April 9, 2013
CHICAGO, April 9, 2013 /PRNewswire/ --Zacks Equity Research highlights
AMERISAFE, Inc. (Nasdaq:AMSF) as the Bull of the Day and Scholastic
Corporation (Nasdaq:SCHL ) as the Bear of the Day. In addition, Zacks Equity
Research provides analysis on GlaxoSmithKline(NYSE:GSK), Novartis AG
(NYSE:NVS) and Sanofi (NYSE:SNY).
Full analysis of all these stocks is available at
Here is a synopsis of all five stocks:
Bull of the Day:
AMERISAFE, Inc. (Nasdaq:AMSF) delivered strong fourth quarter results on
February 27, driven by a big increase in net premiums earned. Earnings per
share for the quarter beat the Zacks Consensus Estimate by 25%, prompting
analysts to revise their estimates significantly higher for both 2013 and
It is a Zacks Rank #1 (Strong Buy) stock.
Although shares of AMERISAFE have risen sharply since the Q4 beat, the
valuation picture still looks reasonable, leaving the stock with plenty of
room to run higher.
AMERISAFE is a specialty provider of hazardous workers' compensation insurance
to small and mid-sized companies.
AMERISAFE delivered better-than-expected fourth quarter results on February
27. The company reported adjusted earnings per share of 49 cents, beating the
Zacks Consensus Estimate by 10 cents. It was a whopping 53% increase over the
same quarter in 2011.
Bear of the Day:
Earnings estimates have fallen sharply for Scholastic Corporation (Nasdaq:SCHL
) following disappointing fiscal 2013 third quarter results and lower
management guidance. It is a Zacks Rank #5 (Strong Sell) stock.
Although shares have sold off since the Q3 report making valuation look a bit
more attractive, investors may want to hold off on this stock until earnings
Scholastic Corp is the world's largest publisher and distributor of children's
Scholastic Corp delivered disappointing results for the third quarter of its
fiscal 2013 on March 21. The company reported a loss of -63 per share, which
was well below the Zacks Consensus Estimate of -39 cents. It was also well
below last year's loss of -32 cents.
Sales slid -19% to $380.5 million, missing the consensus of $384.0 million. It
was the company's 3rd straight top-line miss. This quarter's decline was
driven mostly by the "Children's Book Publishing & Distribution" segment,
which saw sales plunge -30% due to a sharp drop in sales of The Hunger Games
Latest Posts on the Zacks Analyst Blog:
Glaxo Flu Vaccine Approved
GlaxoSmithKline(NYSE:GSK) recently announced the receipt of marketing
authorization for its four-strain seasonal influenza vaccine in Germany and
the UK. The vaccine will be marketed as Influsplit Tetra in Germany and
Fluarix Tetra in the UK.
The vaccine Influsplit Tetra/Fluarix Tetra helps in the prevention of
influenza in adults and children (three years and older) caused by the two
influenza A virus subtypes and the two influenza B virus types contained in
the vaccine. In Europe, it is the first four-strain influenza vaccine to get
approval. It is expected to be launched in the flu season of 2013/2014.
The vaccine gained US Food and Drug Administration (FDA) approval in Dec 2012.
The approval was based on three studies, namely, Fluarix-US-005, FLU-056 and
Fluarix-062. Moreover, Glaxo is currently seeking approval in Australia,
Switzerland and Taiwan. The market also has products like Novartis AG's
(NYSE:NVS) Aggripal and Sanofi's (NYSE:SNY) Vaxigrip and Fluzone.
We note that Glaxo boasts of a strong vaccine portfolio which includes
vaccines like Infanrix/Pediarix, Rotarix, Synflorix and Cervarix.
A few days back, Glaxo received a complete response letter (CRL) from the FDA
for its influenza vaccine candidate, Q-Pan H5N1 (pandemic influenza A virus
monovalent adjuvanted vaccine). The FDA issued the CRL due to an
administrative issue. Glaxo noted in its press release that the issue has
already been resolved and it is working with the FDA to gain approval.
Get the full analysis of all these stocks by going to
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting http://at.zacks.com/?id=7158.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.